GTC Biotherapeutics (fka GTCB)

[rustyboy]

Keitern:

I only have time for a brief reply at the moment.

With the Ovation agreement we quit holding our breath. While
I was confident an agreement would happen, until it's in hand,
some doubt always remains.

We remain most encouraged about where the business of GTC is going and the valuation--about $60 million for the equity today--is absurdly cheap in our view. GTC's stock price behavior is understandable given the cash concern, but in my opinion the 'business risk' for GTC, keeps going down and
with that the valuation should be going up, not down.
I'll save my 'patience jokes' for another time.....

Also, I remain enthusiastic about the CABG indication for Atyrn as I think it offers the quickest and likely, easiest
way for GTC to become 'self-financing' and the quickest path for Ovation to get returns from their investment. As others have said, having Ovation jump onto the transgenics train is a good endorsement as they look like a highly competent organization. By the way, just my guess, but I don't think Ovation was the original partnering candidate talked about earlier.